THERAPIES FOR CHRONIC MYELOID LEUKAEMIA

Professor Tim Hughes
Clinical Director Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI)
& Consultant Haematologist, Royal Adelaide Hospital, South Australia

RESEARCHER PROFILE  (Filmed in Adelaide, South Australia | December 2024)

Professor Tim Hughes is the Chronic Myeloid Leukaemia Group Leader at SAHMRI, Clinical Director in the Precision Cancer Medicine Theme at SAHMRI  and Consultant Haematologist in the Division of Haematology at SA Pathology and at the Royal Adelaide Hospital.

He is also Inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS) and Fellow of the Australian Academy of Science.

Professor Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times. 

He has been recognised for his achievements with several national awards including the GSK Award for Research Excellence in 2017 for pioneering the use of tyrosine kinase inhibitors (TKIs) and the Ramaciotti Medal for Excellence in Biomedical Research in 2019. He was also awarded the International CML Foundation Goldman Prize in 2017 for lifetime contributions to improving outcomes for patients with CML.